Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pneumococcal disease
Pharma
Merck touts Capvaxive's potential to provide protection for kids
Approved 15 months ago as the first pneumococcal disease vaccine for adults, Merck’s Capvaxive has shown potential in those ages 2 to 17.
Kevin Dunleavy
Sep 11, 2025 11:12am
Pfizer enlists Elizabeth Banks for pneumococcal vaccine push
Mar 19, 2025 3:20pm
Merck's new Capvaxive scores key CDC vaccine panel endorsement
Jun 28, 2024 11:44am
Merck's Prevnar rival snags key pediatric nod
Jun 22, 2022 6:45am
Merck's Vaxneuvance makes its case for FDA approval in children
Oct 4, 2021 10:08am
Merck moves a step closer in advancement of its next-gen shot
Aug 25, 2021 9:13am
